drugset
drugset / Trial / NCT06180980

A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants

NCT06180980 ↗

Phase 1 Completed 20 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The main purpose of this study is to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) after meals and on an empty stomach. The study will also evaluate the safety and tolerability of pirtobrutinib (LOXO-305). Participants will stay in this study for up to 53 days (screening through follow-up call).

Timeline

Start
2021-01-04
Primary completion
2021-03-08
Completion
2021-03-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirtobrutinib Other / unclassified 200 mg Oral

Indications

No indication recorded.